Abstract
Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors which have been implicated in breast cancer. The aim of this study was to evaluate FGFR-1, -2, -3, and -4 protein expressions in normal murine mammary gland development, and in murine and human breast carcinomas. Using immunohistochemistry and Western blot, we report a hormonal regulation of FGFR during postnatal mammary gland development. Progestin treatment of adult virgin mammary glands resulted in changes in localization of FGFR-3 from the cytoplasm to the nucleus, while treatment with 17-β-estradiol induced changes in the expressions and/or localizations of FGFR-2 and -3. In murine mammary carcinomas showing different degrees of hormone dependence, we found progestin-induced increased expressions, mainly of FGFR-2 and -3. These receptors were constitutively activated in hormone-independent variants. We studied three luminal human breast cancer cell lines growing as xenografts, which particularly expressed FGFR-2 and -3, suggesting a correlation between hormonal status and FGFR expression. Most importantly, in breast cancer samples from 58 patients, we found a strong association (P < 0.01; Spearman correlation) between FGFR-2 and -3 expressions and a weaker correlation of each receptor with estrogen receptor expression. FGFR-4 correlated with c-erbB2 over expression. We conclude that FGFR-2 and -3 may be mechanistically linked and can be potential targets for treatment of estrogen receptor-positive breast cancer patients.
Similar content being viewed by others
References
Morrison RS, Yamaguchi F, Bruner JM et al (1994) Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 54:2794–2799
Yoshimura N, Sano H, Hashiramoto A et al (1998) The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 89:28–34
Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071
Ahmed NU, Ueda M, Ito AM et al (1997) Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res 7:299–305
Myoken Y, Myoken Y, Okamoto T et al (1996) Expression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of growth. Int J Cancer 65:650–657
Shingu K, Fujimori M, Ito K et al (1998) Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocr J 45:35–43
Bernard RS, Zheng L, Liu W et al (2005) Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146:1145–1153
Powers CJ, McLeskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165–197
Hynes NE, Dey JH (2010) Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 70:5199–5202
Giulianelli S, Cerliani JP, Lamb CA et al (2008) Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 123:2518–2531
Cerliani JP, Guillardoy T, Giulianelli S et al (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res 71:3720–3731
Imagawa W, Pedchenko VK, Helber J et al (2000) Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression. J Cell Physiol 184:222–228
Ishii K, Imamura T, Iguchi K et al (2009) Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocr Relat Cancer 16:415–428
Chodosh LA, Gardner HP, Rajan JV et al (2000) Protein kinase expression during murine mammary development. Dev Biol 219:259–276
Shiang CY, Qi Y, Wang B et al (2010) Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 123:747–755
Turner N, Pearson A, Sharpe R et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085–2094
Institute of Laboratory Animal Resources CoLSNRC (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC
Lanari C, Lamb CA, Fabris VT et al (2009) The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 16:333–350
Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
Vanzulli SI, Soldati R, Meiss R et al (2005) Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26:1055–1063
Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964–4973
Helguero LA, Viegas M, Asaithamby A et al (2003) Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res Treat 79:379–390
Brisken C, O’Malley B (2010) Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2:a003178
Montero GG, Vanzulli SI, Cerliani JP et al (2007) Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res 9:R22
Pandit SG, Govindraj P, Sasse J et al (2002) The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs. Biochem J 361:231–241
Zhu X, Asa SL, Ezzat S (2009) Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol Endocrinol 23:1397–1405
Hollestelle A, Nagel JH, Smid M et al (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121:53–64
Bruzzone A, Vanzulli SI, Soldati R et al (2009) Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice. J Cell Physiol 219:477–484
Lu P, Ewald AJ, Martin GR et al (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 321:77–87
Parsa S, Ramasamy SK, De Langhe S et al (2008) Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. Dev Biol 317:121–131
Pond AC, Herschkowitz JI, Schwertfeger KL et al (2010) Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 70:4868–4879
Johnston CL, Cox HC, Gomm JJ et al (1995) Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 270:30643–30650
Tannheimer SL, Rehemtulla A, Ethier SP (2000) Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2:311–320
Luqmani YA, Graham M, Coombes RC (1992) Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66:273–280
Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023
Fillmore CM, Gupta PB, Rudnick JA et al (2010) Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 107:21737–21742
Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24:3747–3755
Bange J, Prechtl D, Cheburkin Y et al (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840–847
Sharpe R, Pearson A, Herrera-Abreu MT et al (2011) FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17:5275–5286
Gelsi-Boyer V, Orsetti B, Cervera N et al (2005) Comprehensive profiling of 8p11–12 amplification in breast cancer. Mol Cancer Res 3:655–667
Gowardhan B, Douglas DA, Mathers ME et al (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 92:320–327
Martin AJ, Grant A, Ashfield AM et al (2011) FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes 4:72
Zammit C, Barnard R, Gomm JC et al (2001) Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 194:27–34
Kuroso K, Imai Y, Kobayashi M et al (2010) Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 77:231–240
Zhu X, Asa SL, Ezzat S (2010) Genetic and epigenetic mechanisms down-regulate FGF receptor 2 to induce melanoma-associated antigen A in breast cancer. Am J Pathol 176:2333–2343
Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093
Marian C, Ochs-Balcom HM, Nie J et al (2010) FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer 129:702–712
Garcia-Closas M, Chanock S (2008) Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 14:8000–8009
Acknowledgments
The authors thank Julieta Bolado, Bruno Luna, and Pablo DoCampo for their excellent technical assistance. The authors are also grateful to Dr. Ciriano, Roche Argentina, and Dr. Acosta for evaluating Her2; and to Dr Luthy for providing the IBH-6 cell line. MCB received an ICRETT Fellowship from the UICC permitting training in Dr Gutkind’s laboratory at NIH. This study was supported by Sales Foundation, SECyT (PICT 08, No. 989), and CONICET (PIP 2010-2012 N°692). Dr. Hewitt and Dr Molinolo are supported by the Intramural Research Program of the NCI, and the NIDCR from the National Institutes of Health, respectively. JPC, CPP, MCB, AS, and CAL carried out experiments. SIV and AAM analyzed breast cancer samples. MN carried out the statistical analysis of human samples. RV, RM, and EZ provided the cancer samples. SMH prepared the mouse tissue array. CL and CAL conceived the experiments and wrote the paper. All the authors gave final approval to the submitted version.
Conflict of interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cerliani, J.P., Vanzulli, S.I., Piñero, C.P. et al. Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 133, 997–1008 (2012). https://doi.org/10.1007/s10549-011-1883-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1883-6